1. In Vivo
  2. >>Business Strategy

Curing What Ails Alzheimer’s Drug Development

 
• By Rachel Laing, Alessia Deglincerti, and Mark Ratner

Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

IV1712_Alzheimer_1200.jpg

As the drug industry has seen over the past decade with immunotherapy in cancer, success breeds success and opens the door to investment in new targets and rationales. That’s long been the hope in Alzheimer’s disease (AD) drug development, where a hard-to-segment patient population and large, lengthy, expensive trials have continued to frustrate companies. The pharma industry claims to be learning from the past, but the pattern of high-profile, late-stage failures, most recently by Axovant Sciences Ltd. and Merck & Co. Inc., is unbroken. Success remains elusive. (Also see "Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure" - Scrip, 27 September, 2017.) (Also see "Another Nail In Amyloid Hypothesis Coffin? Merck Ends Pivotal BACE Inhibitor Study" - Scrip, 15 February, 2017.)

On the bright side, it is conceivable that in the next two to four years, one of the AD drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By David Wild

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.